Written questions by Tugendhat.

Whether he has had discussions with NICE on the potential merits of innovative brain cancer treatments in Germany that are not currently available on the NHS.

My Rt Hon. Friend, the Secretary of State for Health and Social Care, has had no discussions with the National Institute for Health and Care Excellence (NICE) on the potential merits of innovative brain cancer treatments in Germany that are not currently available on the National Health Service.In England, NICE makes recommendations for the NHS on whether new licensed medicines should be routinely funded by the NHS based on an assessment of clinical and cost effectiveness. The NHS is legally required to fund NICE recommended medicines, normally within three months of final guidance, and cancer medicines are eligible for funding from the point of a positive draft NICE recommendation. NICE aims wherever possible to issue guidance on new medicines close to the time of licensing to ensure that patients are able to benefit from rapid access to clinically and cost effective new medicines.

Whether his Department has made an assessment of the reasons people with brain cancer are seeking treatment outside the UK, particularly in Germany, including the trend in the level of such treatments.

Ensuring patients have access to the latest and most effective treatment options is a top priority for the Government.That is why we are committed to supporting an innovative clinical research ecosystem in the United Kingdom so that patients in this country can be among the first to benefit as we make the National Health Service fit for the future.The Government is supportive of Scott Arthur’s Private Members Bill on rare cancers, which will make it easier for clinical trials into rare cancers, such as brain cancers, to take place in England by ensuring the patient population can be easily contacted by researchers. This will ensure that the NHS will remain at the forefront of medical innovation and is able to provide patients with the newest, most effective treatment options, and ultimately boost survival rates.

What funding provisions are being put in place for hospice care, in the context of rising costs of living and changing needs of the staff.

Palliative care services are included in the list of services an integrated care board (ICB) must commission. This promotes a more consistent national approach and supports commissioners in prioritising palliative care and end of life care. To support ICBs in this duty, NHS England has published statutory guidance and service specifications.We understand the financial pressures faced by the hospice sector which is why we are supporting eligible adult, and children and young people’s hospices in England with a £100 million capital funding boost to ensure they have the best physical environment for care.Additionally, we are also providing £26 million of revenue funding for children and young people’s hospices for 2025/26 and have also recently confirmed the continuation of this vital funding of at least £26 million, as it will be adjusted for inflation, each year from 2026/27 to 2028/29 inclusive. This amounts to approximately £80 million over the next three years.On hospice staff-related costs specifically, independent organisations, such as charities and social enterprises, are free to develop and adapt their own terms and conditions of employment, including pay scales. It is for them to determine what is affordable within the financial model they operate.In the long term, through our Modern Service Framework (MSF), we hope that, by supporting ICBs to commission more strategically, we can move away from grant and block contract models. This would be more sustainable and help hospices plan ahead.I refer the Rt Hon. Member to the Written Ministerial Statement HCWS1087 I gave to the House.